Lineage Cell Therapeutics Files 8-K
Ticker: LCTX · Form: 8-K · Filed: Nov 12, 2025 · CIK: 876343
| Field | Detail |
|---|---|
| Company | Lineage Cell Therapeutics, Inc. (LCTX) |
| Form Type | 8-K |
| Filed Date | Nov 12, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1.75, $21 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, other-event
Related Tickers: LCTX
TL;DR
LCTX filed an 8-K, something happened, details TBD.
AI Summary
Lineage Cell Therapeutics, Inc. filed an 8-K on November 12, 2025, reporting an "Other Event." The filing does not contain specific details about the event, dollar amounts, or dates beyond the filing date itself. The company is incorporated in California and headquartered in Carlsbad.
Why It Matters
This filing indicates a material event has occurred for Lineage Cell Therapeutics, Inc., requiring disclosure to investors, though the specific nature of the event is not detailed in this summary.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for an 'Other Event' without specific negative or positive details, making the immediate risk level low.
Key Numbers
- 001-12830 — Commission File Number (Identifies the company's SEC filing history)
- 94-3127919 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Lineage Cell Therapeutics, Inc. (company) — Registrant
- November 12, 2025 (date) — Date of Report
- California (location) — State of Incorporation
- Carlsbad (location) — City of Principal Executive Offices
FAQ
What specific event is being reported in this 8-K filing?
The filing states 'Other Events' as the item information but does not provide specific details about the nature of the event.
When was this 8-K report filed?
The report was filed on November 12, 2025.
What is the principal executive office address for Lineage Cell Therapeutics, Inc.?
The address is 2173 Salk Avenue, Suite 200, Carlsbad, California, 92008.
What is the Commission File Number for Lineage Cell Therapeutics, Inc.?
The Commission File Number is 001-12830.
What was the former name of Lineage Cell Therapeutics, Inc.?
The former name was BIOTIME INC, with a date of name change on March 28, 1993.
Filing Stats: 404 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2025-11-12 09:25:41
Key Financial Figures
- $1.75 — derson Investors at a purchase price of $1.75 per share in a block transaction under
- $21 million — offering program. The Company received $21 million in gross proceeds, before deducting fee
Filing Documents
- lctx-20251112.htm (8-K) — 39KB
- 0001193125-25-276249.txt ( ) — 138KB
- lctx-20251112.xsd (EX-101.SCH) — 23KB
- lctx-20251112_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On November 12, 2025, Lineage Cell Therapeutics, Inc. (the "Company") sold 12,000,000 common shares to Janus Henderson Investors at a purchase price of $1.75 per share in a block transaction under its at-the-market offering program. The Company received $21 million in gross proceeds, before deducting fees and other expenses payable by it.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lineage Cell Therapeutics, Inc. Date: November 12, 2025 By: /s/ George A. Samuel III Name: Title: George A. Samuel III General Counsel and Corporate Secretary